SCHEMBL5654842

SCHEMBL5654842

OCCc1ccc2nsnc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 6/20 0.47
MAPT P10636 4/20 0.47
GAA P10253 3/20 0.47
PTPN11 Q06124 2/20 0.47
ALOX5 P09917 1/20 0.47
BACE1 P56817 1/20 0.47
LMNA P02545 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
BLM P54132 2/20 0.45
NSD2 O96028 2/20 0.45
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOA1 Q15788 1/20 0.44
RECQL P46063 2/20 0.43
PTPN1 P18031 1/20 0.42
CA2 P00918 1/20 0.41
TXNRD1 Q16881 1/20 0.40
TXNRD3 Q86VQ6 1/20 0.40
TXNRD2 Q9NNW7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262949 0.85 PTPN11 (0.48) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL14944883 0.82 PTPN11 (0.55) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL8229673 0.82 PTPN11 (0.45) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL22900317 0.77 PTPN11 (0.41) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL257319 0.77 PTPN11 (0.48) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL245270 0.77 PTPN11 (0.48) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL4682270 0.77 PTPN11 (0.48) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL3275924 0.77 PTPN11 (0.54) ALDH1A1KDM4EMAPTGAAPTPN11
SCHEMBL5155836 0.75 KDM4E (0.47) ALDH1A1KDM4EMAPTGAAALOX5
Hydrochloric Acid SCHEMBL5957709 0.75 PTPN11 (0.52) ALDH1A1KDM4EMAPTGAAPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186730-B2 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2007-03-06 US disclosed
EP-1392686-B1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2006-10-18 EP disclosed
EP-1343780-B1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2006-09-20 EP disclosed
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2004-10-07 US disclosed
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections SMITHKLINE BEECHAM P.L.C. (GB) 2004-04-22 US disclosed
EP-1392686-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-03-03 EP disclosed
EP-1343780-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM PLC (GB) 2003-09-17 EP disclosed
WO-2002096907-A1 BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2002-12-05 WO disclosed
WO-2002050061-A1 PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198755-A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials NRDC, NUCB2, ASNS ALDH1A1 3130/4885KDM4E 4040/4885MAPT 4296/4885
US-20040077655-A1 Piperazine derivatives for treatment of bacterial infections MYD88, THPO, PIGO ALDH1A1 1678/4885KDM4E 4732/4885MAPT 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.